Looks like they are really emphasizing the diabetes and kidney disease therapeutic potential right now. At the bottom of the blog post, they state: "Resverlogix will be attending two upcoming conferences, The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) to be held in London on May 28-31 and the American Diabetes Association (ADA): 75th Scientific Sessions being held from June 5-9 in Boston. Stay tuned for upcoming Tweets from the conferences @Resverlogix_RVX."

Here is the European Renal Association presentation info for their poster on May 30th:

SP323

EFFECTS OF RVX-208, A FIRST IN CLASS EPIGENETIC BET INHIBITOR, ON KEY RENAL PARAMETERS IN SUBJECTS WITH A HISTORY OF CVD, AND CHRONIC KIDNEY DISEASE (CKD); A POST-HOC ANALYSIS OF PATIENTS FROM THE ASSERT, SUSTAIN AND ASSURE CLINICAL TRIALS

Kamyar Kalantar-Zadeh1, Jan Johansson2, Ken Lebioda3, Christopher Halliday3, Michael Sweeney2, Norman Wong3,

1Univ California Los Angeles (UCLA), David Geffen School Medicine & School Public Health, Los Angeles, CA,

2Resverlogix Inc, Clinical Development, San Francisco, CA, 3Resverlogix Inc, R and D, Calgary, AB, CANADA.

Here is the Diabetes Association presentation info for their poster on June 7th:

1189-P - Effects of the ApoA-I Inducer RVX-208 on Glucose Metabolism in Individuals with Prediabetes

ANDREW L. SIEBEL, MELISSA F. FORMOSA, ALAINA K. NATOLI, MEDINI REDDY-LUTHMOODOO, ANDREW L. CAREY, GERRIT VAN HALL, JIM D. OTVOS, KERRY-ANNE RYE, JAN JOHANSSON, ALLAN GORDON, NORMAN WONG, PHILIP BARTER, STEPHEN J. DUFFY, BRONWYN A. KINGWELL, Melbourne, Australia, Copenhagen, Denmark, Raleigh, NC, Sydney, Australia, Calgary, AB, Canada